Introduction {#sec1-1}
============

Adrenocortical carcinoma (ACC) accounts for most of the primary adrenal gland malignancies. It is a fatal disease because of its rapid progression and high mortality risk (Kerkhofs et al., 2013; Else et al., 2014a). Almost two-thirds of patients experienced tumor recurrence within 2 years after curative surgery, including local recurrence and metastasis (Amini et al., 2016). Surgical resection of the primary tumor is still the unique curative treatment modality for non-metastatic ACCs (Stigliano et al., 2016). Adjuvant therapy in conjunction with surgery could delay tumor recurrence, but the improvement in the overall survival is controversial (Terzolo et al., 2007; Else et al., 2014b). Reoperation, mitotane therapy and chemotherapy are the pivotal choices for advanced and recurrent ACCs. The most responsive combination therapy, EDP-M (etoposide, doxorubicin, cisplatin with mitotane), was superior to the Sz-M (streptozotocin with mitotane) regimen and had a similar incidence of adverse events in the FIRM-ACT trial (First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment) (Fassnacht et al., 2012). To facilitate consecutive adjuvant therapy, accurate risk evaluation before treatment is important for subsequent selection of the management strategy. Previous studies on predicting ACC survival are scarce due to the low incidence of ACC and lack of a large population. The aim of this study is to define the prognostic factors in ACC patients and to evaluate the discrimination ability of a different stage system using a population-based oncologic database.

Materials and Methods {#sec1-2}
=====================

Patients and Methods Study population {#sec2-1}
-------------------------------------

The Surveillance, Epidemiology and End Results (SEER) database (1973-2014, Nov 2016 submission) was queried using the International Classification of Diseases for Oncology codes third edition (ICD-O-3). Primary consecutive screen conditions were set as the primary tumor site (Site recode B ICD-O-3/WHO 2008: Adrenal Gland), adults (age ≥18 years), histology type (ICD-O-3: 8370), and first primary tumor with survival time, unilateral tumor. After multiple rounds of screening, 749 records were identified. Related variable information was extracted, including age, sex, race, tumor laterality, marital status at diagnosis, treatment modality of primary site, regional lymph node dissection (RLND), radiation therapy, chemotherapy, tumor size, tumor stage, cause of death, survival status, and survival time. The clinical tumor stage was defined using the 7th edition of the American Joint Committee on Cancer (AJCC) staging system and European Network for the Study of Adrenal Tumors (ENSAT) stage system. The AJCC stage group consisted of stages I (T1N0M0), II (T2N0M0), III (T1\~2N1M0 or T3N0M0) and IV (T3N1M0, T4N0M0 or TanyNanyM1). The ENSAT stage system consisted of stages I (T1N0M0), II (T2N0M0), III (T3\~4N0M0 or T1\~4N1M0) and IV (TanyNanyM1) (Fassnacht et al., 2009; Lughezzani et al., 2010). We also modified the tumor stage by merging stage I and stage II of AJCC stage group and ENSAT stage (sAJCC stage group: stage I/II, III, IV; sENSAT stage: stage I/II, III, IV). Considering some underutilized data (e.g., collaborative stages of tumor extension, tumor size, lymph nodes, and metastasis at diagnosis, but no concluded tumor stage), we re-staged the tumor stage of each case compatible with the UICC/AJCC T.N.M stage system based on the Collaboration Stage Data Collection System version 02.05 (CS version 02.05, <http://web2.facs.org/cstage0205/adrenalgland/AdrenalGlandschema.html>).

Statistical analysis {#sec2-2}
--------------------

Continuous variables were presented as the median with interquartile range (IQR) in brackets. Category variables were presented as counts. For regression analysis, we used univariate Cox regression to screen potential confounding variables. Variables with P ≤ 0.1 in univariate analysis were included in the multivariate Cox regression. The hazard ratio (HR) and 95% confidence interval (95% CI) was used to show the risks. The discrimination ability was calculated using the Harrell C index (C-index) (Harrell et al., 1982). All tests were two-sided, and a P value \< 0.05 was considered statistically significant. All statistical analyses were performed using R software (Version 3.3.1, <https://www.r-project.org>) and Stata 15 (StataCorp LLC, TX, USA).

Results {#sec1-3}
=======

The demographic characteristics are shown in [Table 1](#T1){ref-type="table"}. A total of 749 patients with a median age of 55 years (IQR 44-65) were identified between 1973 and 2014. The population con-sisted of 454 (60.6%) female and 205 (39.4%) male patients (pts). The main race was white race (631 pts, 84.4%). The locations of the lesions were similar (402 left and 347 right ACCs). The median tumor size was 11 cm with an IQR (8-15 cm). Marital status at diagnosis was redefined as married (440 pts) and unmarried (280 pts). Treatment modality included no surgery of primary site (198 pts) and surgery of primary site (545 pts). Regional lymph node removal was performed in 145 patients (20.1%) and 111 (14.8%) patients underwent adjuvant radiation therapy. Detailed tumor stages, including T.N.M stage, AJCC stage group and ENSAT stage, were listed in [Table 1](#T1){ref-type="table"}. Among the 749 patients, 486 patients died during the follow-up; 421 patients died of ACC-specific causes, and the other 65 died of other causes. The overall median survival time was 22 (95%CI, 18-25) months. The median survival time were 57 months for ENSAT stage I, 67 months for stage II, 21 months for stage III and 7 months for stage IV.

###### 

Characteristics of the Study Population

  Characteristics     Value                     Number of population
  ------------------- ------------------------- ----------------------
  Age                 55 (44 - 65) years        749
  Sex                 Female                    454 (60.6%)
                      Male                      205 (39.4%)
  Race                Black                     59 (7.9%)
                      White                     631 (84.4%)
                      Other                     58 (7.7%)
  Laterality          Left                      402 (53.7%)
                      Right                     347 (46.3%)
  Marital             Married                   440 (61.1%)
                      Unmarried                 280 (38.9%)
  Treatment           Surgery of primary site   545 (73.4%)
                      No surgery                198 (26.6%)
  Regional LND        No                        577 (79.9%)
                      Yes                       145 (20.1%)
  Radiation           No/unknown                638 (85.2%)
                      Yes                       111 (14.8%)
  Chemotherapy        No/unknown                433 (57.8%)
                      Yes                       316 (42.2%)
  Tumor size          11 (8.0 - 15) cm          692
  T stage             T1                        38 (5.5%)
                      T2                        306 (44.6%)
                      T3                        150 (21.8%)
                      T4                        193 (28.1%)
  N stage             N0                        590 (86.3%)
                      N1                        94 (13.7%)
  M stage             M0                        460 (61.4%)
                      M1                        289 (38.6%)
  AJCC stage group    I                         30 (4.1%)
                      II                        230 (31.4%)
                      III                       101 (13.8%)
                      IV                        371 (50.7%)
  ENSAT stage         I                         30 (4.1%)
                      II                        230 (31.2%)
                      III                       189 (25.6%)
                      IV                        289 (39.1%)
  sAJCC stage group   I/II                      271 (36.2%)
                      III                       101 (25.2%)
                      IV                        371 (38.4%)
  sENSAT stage        I/II                      271 (36.5%)
                      III                       189 (13.6%)
                      IV                        289 (49.9%)
  Survival status     Alive                     263 (35.1%)
                      Dead                      486 (64.9%)

LND, lymph node dissection; AJCC, American Joint Committee on Cancer; ENSAT, European Network for the Study of Adrenal Tumors; sENSAT stage, simplified ENSAT stage; sAJCC stage group, simplified AJCC stage group.

[Table 2](#T2){ref-type="table"} shows both univariate and multivariate analyses of the overall survival. In univariate analysis, age (P\< 0.001), treatment modality of primary site (P\< 0.001), chemotherapy (P\< 0.001) and tumor stage (P\< 0.001) were associated with overall survival. Sex, race, laterality, marital status, lymph node dissection, radiation therapy and tumor size were not significantly associated. In multivariate Cox regression, age, treatment modality, chemotherapy and tumor T.N.M stage were independent risk factors. T2 stage patients have similar overall survival (HR 1.377, 0.820-2.310, P= 0.226). Chemotherapy was a protective factor with hazard ratio 0.772 (95%CI, 0.602-0.990). We used the above independent risk factors to construct survival models with the AJCC stage group or ENSAT stage system. The results consistently showed that mortality risk increased with the increase of the tumor stage. No survival difference between stages II and stage I was observed in the AJCC stage group and ENSAT stage systems. [Table 3](#T3){ref-type="table"} shows both univariate and multivariate analyses of the cancer-specific survival. In univariate analysis, age (P\< 0.001), treatment modality (P\< 0.001), chemotherapy (P\< 0.001) and tumor stage (P\< 0.001) were correlated with cancer-specific survival. Sex, race, tumor location, marital status, lymph node dissection, radiation and tumor size did not affect the survival outcome. In accordance with the overall survival model, age, treatment modality and tumor T.N.M stage were independent prognostic factors in multivariate regression. Chemotherapy did not significantly improve cancer specific survival (HR 0.771, 0.591-1.005, P= 0.055). The effect size was marginal significance because when using efron method to deal with the ties, the hazard ratio was 0.748 (95%CI, 0.572-0.979, P=0.034). A multivariate model with age, treatment modality and AJCC stage group (or ENSAT stage) showed similar results as with aforementioned overall survival model. Stage I had no cancer-specific survival difference with stage II. As the clinical stage increased, the mortality risk also increased.

###### 

Predictors of Overall Survival for Adrenocortical Carcinoma

  Variables                  Univariate analysis    Multivariate analysis                                                         
  -------------------------- ---------------------- ------------------------------------------ ------------ ------- ------------- ------------
  Age                        1.014                  1.007-1.020                                P \< 0.001   1.015   1.007-1.022   P \< 0.001
  Sex                        Reference Female                                                                                     
   Male                      1.126                  0.932-1.361                                0.219                              
  Race                       Reference Black                                                                                      
   White                     1.043                  0.741-1.469                                0.809                              
   Other                     1.095                  0.690-1.738                                0.701                              
  Laterality                 Reference Left                                                                                       
   Right                     0.987                  0.820-1.189                                0.894                              
  Marital                    Reference Married                                                                                    
   Unmarried                 0.974                  0.800-1.185                                0.79                               
  Treatment                  Reference No surgery                                                                                 
   Surgery of primary site   0.214                  0.175-0.263                                P \< 0.001   0.28    0.208-0.378   P \< 0.001
  Regional LND               Reference No                                                                                         
   Yes                       0.819                  0.645-1.041                                0.103                              
  Radiation                  Reference No/unknown                                                                                 
   Yes                       1.05                   0.802-1.373                                0.725                              
  Chemotherapy               Reference No/unknown                                                                                 
   Yes                       1.423                  1.179-1.717                                P \< 0.001   0.772   0.602-0.990   0.042
  Tumor size                 0.998                  0.983-1.014                                0.826                              
  T stage                    Reference T1                                                                                         
   T2                        1.368                  0.818-2.288                                0.233        1.377   0.820-2.310   0.226
   T3                        2.196                  1.293-3.729                                0.004        2.388   1.386-4.114   0.002
   T4                        3.346                  1.990-5.626                                P \< 0.001   1.599   0.929-2.754   0.09
  N stage                    Reference N0                                                                                         
   N1                        3.094                  2.383-4.018                                P \< 0.001   1.836   1.356-2.486   P \< 0.001
  M stage                    Reference M0                                                                                         
   M1                        4.018                  3.314-4.871                                P \< 0.001   2.574   1.927-3.437   P \< 0.001
  AJCC stage group           Reference Stage I      Adjusted[\*](#t2f1){ref-type="table-fn"}                                      
   II                        1.185                  0.650-2.159                                0.58         1.199   0.657-2.188   0.555
   III                       2.144                  1.151-3.995                                0.016        2.341   1.252-4.378   0.008
   IV                        4.837                  2.707-8.643                                P \< 0.001   3.562   1.969-6.443   P \< 0.001
  ENSAT stage                Reference Stage I      Adjusted[\*](#t2f1){ref-type="table-fn"}                                      
   II                        1.185                  0.650-2.159                                0.579        1.17    0.641-2.135   0.61
   III                       2.303                  1.268-4.183                                0.006        2.332   1.280-4.249   0.006
   IV                        6.196                  3.454-11.114                               P \< 0.001   4.515   2.465-8.270   P \< 0.001
  sAJCC stage group          Reference Stage I/II   Adjusted[\*](#t2f1){ref-type="table-fn"}                                      
   III                       1.853                  1.350-2.544                                P \< 0.001   2.01    1.459-2.769   P \< 0.001
   IV                        4.188                  3.349-5.236                                P \< 0.001   3.102   2.396-4.016   P \< 0.001
  sENSAT stage               Reference Stage I/II   Adjusted[\*](#t2f1){ref-type="table-fn"}                                      
   III                       1.991                  1.530-2.592                                P \< 0.001   2.05    1.569-2.679   P \< 0.001
   IV                        5.365                  4.249-6.774                                P \< 0.001   4.024   3.014-5.373   P \< 0.001

95% CI, 95% confidence interval; LND, lymph node dissection; AJCC, American Joint Committee on Cancer; ENSAT, European Network for the Study of Adrenal Tumors; sENSAT stage, simplified ENSAT stage; sAJCC stage group, simplified AJCC stage group;

adjusted by age, treatment, chemotherapy.

###### 

Predictors of Cancer Specific Survival for Adrenocortical Carcinoma

  Variables                  Univariate analysis    Multivariate analysis                                                          
  -------------------------- ---------------------- ------------------------------------------ ------------ ------- -------------- ------------
  Age                        1.01                   1.004-1.017                                0.003        1.012   1.004-1.020    0.005
  Sex                        Reference Female                                                                                      
   Male                      1.08                   0.882-1.323                                0.458                               
  Race                       Reference Black                                                                                       
   White                     1.242                  0.839-1.838                                0.28                                
   Other                     1.301                  0.779-2.171                                0.315                               
  Laterality                 Reference Left                                                                                        
   Right                     0.989                  0.811-1.206                                0.912                               
  Marital                    Reference Married                                                                                     
   Unmarried                 0.93                   0.753-1.148                                0.498                               
  Treatment                  Reference No surgery                                                                                  
   Surgery of primary site   0.206                  0.166-0.256                                P \< 0.001   0.263   0.192-0.362    P \< 0.001
  Regional LND               Reference No                                                                                          
   Yes                       0.88                   0.685-1.130                                0.317                               
  Radiation                  Reference No/unknown                                                                                  
   Yes                       1.121                  0.848-1.482                                0.424                               
  Chemotherapy               Reference No/unknown                                                                                  
   Yes                       1.497                  1.225-1.828                                P \< 0.001   0.771   0.591-1.005    0.055
  Tumor size                 1.001                  0.985-1.018                                0.886                               
  T stage                    Reference T1                                                                                          
   T2                        1.912                  1.006-3.633                                0.048        1.928   1.012-3.676    0.046
   T3                        3.057                  1.586-5.891                                0.001        3.365   1.723-6.572    P \< 0.001
   T4                        4.815                  2.523-9.186                                P \< 0.001   2.321   1.191-4.521    0.013
  N stage                    Reference N0                                                                                          
   N1                        2.965                  2.240-3.926                                P \< 0.001   1.718   1.250-2.363    0.001
  M stage                    Reference M0                                                                                          
   M1                        4.229                  3.444-5.193                                P \< 0.001   2.663   1.955-3.626    P \< 0.001
  AJCC stage group           Reference Stage I      Adjusted[\*](#t3f1){ref-type="table-fn"}                                       
   II                        1.744                  0.806-3.772                                0.158        1.777   0.820-3.848    0.145
   III                       3.084                  1.396-6.812                                0.005        3.393   1.531-7.520    0.003
   IV                        7.453                  3.509-15.831                               P \< 0.001   5.472   2.548-11.752   P \< 0.001
  ENSAT stage                Reference Stage I      Adjusted[\*](#t3f1){ref-type="table-fn"}                                       
   II                        1.745                  0.807-3.775                                0.157        1.74    0.803-3.769    0.16
   III                       3.43                   1.591-7.395                                0.002        3.509   1.624-7.586    0.001
   IV                        9.537                  4.475-20.322                               P \< 0.001   6.848   3.154-14.872   P \< 0.001
  sAJCC stage group          Reference Stage I/II   Adjusted[\*](#t3f1){ref-type="table-fn"}                                       
   III                       1.86                   1.316-2.627                                P \< 0.001   2.021   1.425-2.866    P \< 0.001
   IV                        4.501                  3.535-5.732                                P \< 0.001   3.313   2.507-4.379    P \< 0.001
  sENSAT stage               Reference Stage I/II   Adjusted[\*](#t3f1){ref-type="table-fn"}                                       
   III                       2.068                  1.554-2.751                                P \< 0.001   2.133   1.597-2.851    P \< 0.001
   IV                        5.759                  4.479-7.406                                P \< 0.001   4.236   3.104-5.781    P \< 0.001

95% CI, 95% confidence interval; LND, lymph node dissection; AJCC, American Joint Committee on Cancer; ENSAT, European Network for the Study of Adrenal Tumors; sENSAT stage, simplified ENSAT stage; sAJCC stage group, simplified AJCC stage group;

adjusted by age, treatment, chemotherapy.

[Table 4](#T4){ref-type="table"} shows the discrimination ability for predicting oncologic outcomes in ACCs. Compared with the models with the predictors of age, treatment modality, chemotherapy and tumor stage, the C index of the models with unique predictor of tumor stage (including T.N.M stage, AJCC stage group, or ENSAT stage) was not remarkably reduced in AJCC stage group and sAJCC stage group. Tumor stage was the mainstay in the prognostic models and contributed to the dominant predictive accuracy. Models with the ENSAT stage as a predictor had a larger C index than models with the AJCC stage group (Larger C index means better discrimination ability). These results consistently showed better discrimination ability for the ENSAT stage than for the AJCC stage group regarding overall survival and cancer-specific survival. Additionally, the ENSAT stage was much closer to the T.N.M stage.

###### 

Discrimination Ability (Harrell C index) Comparison of Different Stage System Model

  Predicted outcomes          Embedment of other factors                  Harrell concordance index                           
  --------------------------- ------------------------------------------- --------------------------- ------- ------- ------- -------
  Overall mortality           No                                          0.721                       0.698   0.718   0.697   0.717
  Overall mortality           Embedment[\*](#t4f1){ref-type="table-fn"}   0.767                       0.759   0.766   0.758   0.764
  Cancer specific mortality   No                                          0.737                       0.706   0.725   0.704   0.723
  Cancer specific mortality   Embedment[\*](#t4f1){ref-type="table-fn"}   0.776                       0.765   0.771   0.761   0.767

including age, treatment, chemotherapy; sENSAT stage, simplified ENSAT stage; sAJCC stage group, simplified AJCC stage group.

Discussion {#sec1-4}
==========

In this study, we defined four independent prognostic factors that affect overall and cancer-specific survival. Patients with younger age, surgical resection of primary lession, chemotherapy and low tumor stage had a better prognosis. Increased age decreased the overall survival. Along with the increase in age, the risk of death and tumor progression increased. On the other hand, the survival natural risk of elder increased by the age. The effect of primary site surgery decreased the overall and cancer specific mortality risk. This was consistent with previous studies. Considering this article derived from a observational cancer database. The selection bias probably contributed to the result. For example, patients with good conditions or good prognostic characteristics prone to receive surgical management and had better prognosis. Sex, race, marital status, tumor location, regional LND, radiotherapy and tumor size had no effect on the cancer survival in ACC patients. Moreover, we did not find any survival difference between stages I and stage II ACC patients in this study. Stage I is different from stage II in terms of tumor size with a cutoff of 5 cm, which could contribute to the laparoscopic indication. However, laparoscopic adrenalectomy was not strongly recommended in ACC management guidelines (Stigliano et al., 2016). Moreover, tumor size was not an independent prognostic factor in any model. The value of differentiating between stages I and II remains to be discussed. The staging system needs refinement. Our study also showed that the ENSAT stage system had better predictive ability than the AJCC stage group. The value of the C-index statistic ranges from 0.5 to 1 (100% correct prediction). The prognostic prediction model with a higher value of C-index was regarded as the better model. The C-index of the prognostic model with age, treatment, chemotherapy and ENSAT stage were 0.766 and 0.771 for overall and cancer-specific survival. We also modified the tumor stage by merging stage I and stage II into one category, and resulted in sAJCC stage group and sENSAT stage. Decreased C index was no more than 0.4%. The results showed relatively acceptable predictive ability for our prognostic model.

Compared with previous studies, our research did not adjust for some potential confounders. For instance, the clinical manifestation was concluded as a prognostic factor. Approximately 40-60% patients manifested clinical symptoms that were mainly derived from tumor-derived hormone excess (Fassnacht et al., 2011). Patients with functional tumors were deemed to have a poor prognosis in some studies (Ayala-Ramirez et al., 2013; Else et al., 2014b). In several studies (Else et al., 2014b; Margonis et al., 2016b), cortisol instead of androgen or other functional hormones affected the recurrence and overall survival. However, controversy remained about the impact of tumor hormone function (Loncar et al., 2015; Scollo et al., 2016). Surgery experience is important for tumor control. The surgical margins are somewhat related to the surgeon's experience. R1 (microscopically positive) and (or) R^2^ (macroscopically positive) patients have a poorer prognosis than R0 (microscopically negative) patients (Kim et al., 2016; Margonis et al., 2016a; Margonis et al., 2016b; Scollo et al., 2016). R0 was difficult to achieve, especially because skill was required. In Margonis' retrospective multi-center study, approximately 68.4% of R0 resection was achieved in ACC patients (Margonis et al., 2016b). Newly diagnosed cases should be referred to a centralized medical center (Hermsen et al., 2012; Abdel-Aziz et al., 2015). The surgical modality was also a critical factor. Open surgical resection was proven to have a significant survival benefit over laparoscopic surgery (Gaujoux et al., 2012; Miller et al., 2012; Cooper et al., 2013; Machado et al., 2015; Sgourakis et al., 2015; Autorino et al., 2016; Huynh et al., 2016). Therefore, open adrenalectomy was recommended in the guidelines (Funder et al., 2016; Stigliano et al., 2016), but not all studies were consistent (Lombardi et al., 2012; Fossa et al., 2013; Donatini et al., 2014). This may be derived from the small population in these studies. The necessity of regional lymph node resection is controversial (Reibetanz et al., 2012; Gerry et al., 2016; Nilubol et al., 2016). Lymphadenectomy was not a standard procedure of adrenalectomy in ACC treatment (Stigliano et al., 2016). Our results also did not support the survival benefit of lymph node dissection. Nevertheless, lymph node dissection could pathologically stage the lymph node stage from another perspective. The benefit of adjuvant mitotane administration after surgery remains controversial due to the low incidence of ACC, and no large randomized trial was performed (Terzolo et al., 2007; Fassnacht et al., 2012; Terzolo et al., 2013; Loncar et al., 2015; Maiter et al., 2016; Postlewait et al., 2016). Mitotane could be effective for certain patients. Predictors of response to mitotane therapy and other cytotoxic drugs could facilitate individualized treatment. Radiation was another palliative choice. However, there was no consensus on the ef-fect of adjuvant radiotherapy (Habra et al., 2013; Sabolch et al., 2015). Radiation therapy was deemed to ameliorate symptoms and reduce local recurrence (Fassnacht et al., 2006), but it did not improve the overall survival outcome (Stigliano et al., 2016).

There are numerous controversies in ACC treatment due to low incidence and scattered geographic distribution of this disease. The above controversies in different studies are possibly due to the sample size, number of events, and different adjusted models. Concise and sufficient predictive models are preferable in future studies. There are several limitations in our study. This study is based on the SEER database and, therefore, has the intrinsic bias of an observational study. The aforementioned confounders were not included because lack of the related data. Additionally, missing values pose a great challenge to the application of SEER data. In terms of the C index, our predictive models have relatively acceptable discrimination ability.

In conclusion, our study demonstrated that age, surgery of primary site, chemotherapy and tumor stage were prognostic factors for overall and cancer-specific mortality in ACC patients. Among these factors, tumor stage had a dominant effect. The ENSAT stage had better discrimination ability than the 7th AJCC stage group. Further multi-center prospective studies are still needed to validate these outcomes.
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